1 / 46

Diabetes Mellitus

Diabetes Mellitus. Estimated prevalence of diabetes worldwide in 2025. Number of persons. <5,000 5,000 – 74,000 75,000 – 349,000 350,000 – 1,500,000 >1,500,000 No data available. A projected 300 million people with diabetes worldwide by 2025.

hallie
Download Presentation

Diabetes Mellitus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Diabetes Mellitus

  2. Estimated prevalence of diabetes worldwide in 2025 Number of persons <5,000 5,000 – 74,000 75,000 – 349,000 350,000 – 1,500,000 >1,500,000 No data available A projected 300 million people with diabetes worldwide by 2025 WHO. The World Health Report 1998; 91; King H, et al.Diabetes Care 1998; 21:1414–1431.

  3. Pathophysiology- Type 2 DM • 1. Progressive beta cell dysfunction: -Reduced Insulin secretion in response to serum glucose • 2. Insulin resistance: genetic -increases with age and weight. - glucotoxicity - lipotoxicity

  4. Pathophyisiology-T2DM • 3. Impaired insulin processing: proinsulin ratio increase to 40% in T2DM from a nl ratio of 10-15%

  5. Pathophysiology -Type 1DM • Epidemiology: - bimodal: a. one peak at 4-6 years of age b. second in early puberty (10-14 years) • M=F.

  6. Genetic susceptibility -T1DM  •  • No family history: 0.4 % •  • affected mother: 2 - 4 % •  • affected father: 5 to 8 % •  • both parents affected: 30 % •  • Non-twin sibling of affected patient: 5 % •  • Dizygotic twin: 8 % •  • Monozygotic twin: 50 % lifetime risk

  7. Environmental factors-T1DM    • Viral infections •  • Immunizations •  • Diet: cow's milk at an early age •  • Vitamin D deficiency •  • Perinatalfactors:maternal age, h/o pre-eclampsia, and neonatal jaundice • Low birth weight decreases the risk of developing type 1 diabetes

  8. Type 1 versus type 2 diabetes  1 • Body habitus : T2DM: overweight T1DM: not overweight and often have a recent history of weight loss. 2 • Age : T2DM :after the onset of puberty. T1DM bimodal: 4 -6 yrs, and10 -14 yrs

  9. 3• Insulin resistance : acanthosisnigricans,HTN, dyslipidemia, and PCOS 4• FH: type 2 > type 1 5• Autoimmune Abs: T1DM: +:GAD, tyrosine phosphatase (IA2), and/or insulin Abs T2DM: 30 % have + Abs

  10. Insulin resistance and -cell dysfunction Increased lipolysis and release of free fatty acids Elevated circulating FFA lipotoxicity High insulin demand -Cell dysfunction Insulin resistance glucotoxicity Decreased glucose uptake into glucose output Hyperglycemia muscle and adipose tissue and raised hepatic Type 2 diabetes

  11. Beta-cell function progressively declines 100 Diabetes diagnosis 80 60 Beta-cell function (%, HOMA) 40 20 Extrapolation of beta-cell function prior to diagnosis 0 –12 –10 –8 –6 –4 –2 0 2 4 6 8 Years from diagnosis HOMA: homeostasis model assessmentLebovitz. Diabetes Reviews1999;7:139–53 (data are from the UKPDS population: UKPDS 16. Diabetes 1995;44:1249–58)

  12. Genetic susceptibilty- T2DM - T2DM is 2-6x (blacks> whites) • 39% have at least one parent with the disease • monozygotic twin: 90 % • The lifetime risk for a first-degree relative of a pt with T2DM is 5-10 x higher than age- & wt-matched

  13. ROLE OF DIET, OBESITY, AND INFLAMMATION • Increasing weight and less exercise • Obesity epidemic • Increasing T2DM in children and adolescents

  14. MAJOR RISK FACTORS ( Type2DM) - FH of DM - Overweight (BMI > 25 kg/m2) -physical inactivity -Race/ethnicity (African-Americans, Hispanic-Americans) - h/o IFG or IGT -History of GDM or delivery of a baby weighing >9 lbs -Signs of insulin resistance or conditions associated with insulin resistance : *Hypertension ( 140/90 mmHg in adults) *HDL cholesterol 35 mg/dl (0.90 mmol/l) and/or a triglyceride level 250 mg/dl (2.82 mmol/l) *Polycystic ovary syndrome *acanthosisnigricans

  15. Symptoms • Polyuria, increased frequency of urination, nocturia. • Increased thirst, and dry mouth • Weight loss • Blurred vision • Numbness in fingers and toes • Fatigue • Impotence (in some men)

  16. Signs • Weight loss: muscle weakness • Decreases sensation • Loss of tendon reflexes • Foot Inter-digital fungal infections • Retinal changes by fundoscopy

  17. Criteria for the diagnosis of diabetes 1. A1C ≥6.5 %. * • 2. FPG ≥126 mg/dL. Fasting is defined as no caloric intake for at least 8 h.* • 3. Two-hour plasma glucose ≥200 mg/dLduring an OGTT. 75 g anhydrous glucose dissolved in water.* • 4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL . * In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.

  18. Diabetes Prevention-DPP trial 3234 obese (average BMI 34 kg/m2) age 25-85 yrs at high risk for DM (Obese+ IFG/IGT) were randomized to: • 1. Intensive lifestyle changes: 7 % wt loss ( low-fat diet and exercise for 150 min/ wk) • 2. metformin (850 mg BID) + information on diet and exercise • 3. Placebo plus information on diet and exercise

  19. DPP • The intensive lifestyle and metformin interventions reduced the cumulative incidence of diabetes by 58 and 31 %, respectively compared to placebo.

  20. DPP • The diet and exercise group lost an average of 6.8 kg (7%) of wt / 1st yr. • At 3 years, fewer patients in this group developed diabetes (14 versus 22 and 29 % in the metformin and placebo groups) • Lifestyle intervention was effective in men and women in all age groups and in all ethnic groups.

  21. DPP • 16 % reduction in DM risk for every kg lost • Improvements in insulin sensitivity and insulin secretion, correlated directly with decreased risk of diabetes

  22. Management of Type2DM • 1. Lifestyle modifications: • - Medical nutrition therapy • - increased physical activity • - wt reduction • 2. Oral Drug Therapy/Noninsulin sc therapy • 3. Insulin therapy

  23. Key challenges of type 2 diabetes: outcome Ford et al (NHANES). Diabetes Care 2008;31:102–4 43% of patients do notachieve glycaemic targets (HbA1c<7%)

  24. Current available Therapy • 1. Biguanides: Metformin • -decrease hepatic glucose output • -increases glucose utilization in peripheral tissues (such as muscle and liver) • -antilipolytic effect • -increases intestinal glucose utilization • Efficacy : HbA1c reduction by 1-1.5%

  25. Side Effects: GI upset initially, Lactic acidosis ( 9 cases per 100,000 person-years of exposure)e ) • C/I : renal impairment S.Cr > 1.5 mg/dl males, and S.Cr > 1.4 Females, liver failure, advanced heart failure, sepsis, hypotension.

  26. Drug therapy-2 • 2. Sufonylureas and Meglitinides: Glibenclamide, Repagnilide • - Mechanism: activate SU receptor, stimulate insulin secretion • - Efficacy : HbA1c reduction 1-2 % ( SU), <1% Glinides • - S/E: Hypoglycemia, wt gain • - C/I: pregnancy,

  27. Drug therapy-3 • 3. Alpha- glucosidase inhibitors: Acarbose • - inhibits GI glucose absorption • - prominent GI S/E • - modest HbA1c reductions 0.6%

  28. 4. Thiazolidinediones: Pioglitazones,Rosiglitazones • - PPAR Gamma agonists • -insulin sensitizer on adipose tissue, liver, skeletal muscles. • -S/E: fluid retention-edema,CHF, Hepatotoxicity, bone fractures, macular edema • -Efficacy: HbA1c reduction 1-1.5 %

  29. Drug therapy-3 • 5. Incretin based therapy: • a. DPP4 Inhibitors: • - inhibit Dipeptidylpeptidase 4 enzyme which inactivates native GLP-1 • - given orally • - Efficacy:HbA1c reduction 0.6 -0.8 %, up to 1% if higher baseline HbA1c (>9%) • -S/E: ? Pancreatitis, hepatotoxicity, Skin reactions

  30. b. GLP1 agonists: • Exenetide: synthetic exendin4, from saliva of Gila monster, 53% homology with natural GLP1. • - augments insulin release (glucose- dependent ). • - slows gastric emptying, • -suppresses inappropriately elevated glucagon levels, and leads to weight loss • - HbA1c reduction 1.1% • -S/E : GI (nausea), acute pancreatitis,acute renal failure.

  31. Drug therapy 4 Liraglutide :GLP-1 analog, binds to serum albumin resulting in slower degradation, • -Once daily injection • - HbA1c reduction of 1.5% • -significant weight reduction • - S/E: GI, pancreatitis, ? Thyroid C-cell hyperplasia/malignancy in animal studies.

  32. 6. Amylinanalogues:AMYLIN is a 37-amino acid peptide that is stored in pancreatic beta cells and is co-secreted with insulin . Amylin is deficient in type 1 diabetes and relatively deficient in insulin-requiring type 2 diabetes • -slowed gastric emptying, • -regulation of postprandial glucagon • - reduction of food intake

  33. Drug therapy 5 • PRAMLINTIDE : amylin analog • -approved for both type 1 and insulin-treated type 2 diabetes. • -effects are glucose-dependent and are overridden as serum glucose levels fall. It does not cause hypoglycemia • -HbA1c reduction < 1% • S/E : nausea, increase hypoglycemia risk if insulin dose not reduced.

  34. Insulins 1. Ultra-short acting : Aspart-Lispro-Glulisine • 2. Short acting: Regular • 3. Intermediate acting : NPH • 4. intermediate—long : Insulin Detimir • 5. Long acting : Insulin Glargine

  35. Most therapies result in weight gain over time UKPDS: up to 8 kg in 12 years ADOPT: up to 4.8 kg in 5 years 100 8 Insulin (n=409) 7 6 96 5 Glibenclamide (n=277) Change in weight (kg) 4 Weight (kg) 92 3 2 88 1 Metformin (n=342) 0 0 3 6 9 12 0 0 1 2 3 4 5 Years from randomisation Years Conventional treatment (n=411); diet initially then sulphonylureas, insulin and/or metformin if FPG >15 mmol/L Rosiglitazone Metformin Glibenclamide UKPDS 34. Lancet 1998:352:854–65. n=at baseline; Kahn et al (ADOPT). NEJM 2006;355(23):2427–43

  36. Over time, glycaemic control deteriorates Conventional* Rosiglitazone UKPDS ADOPT Glibenclamide Metformin Metformin Glibenclamide 9 Insulin 8.5 8 8 7.5 7.5 Median HbA1c (%) 7 Recommended treatment target <7.0%† 7 6.5 6.5 6 6.2% – upper limit of normal range 0 1 2 3 4 5 0 2 4 6 8 10 6 Time (years) Years from randomisation *Diet initially then sulphonylureas, insulin and/or metformin if FPG>15 mmol/L; †ADA clinical practice recommendations. UKPDS 34, n=1704 UKPDS 34. Lancet 1998:352:854–65; Kahn et al (ADOPT). NEJM 2006;355(23):2427–43

  37. THANK YOU

  38. Thank You

More Related